First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study-Reference-Cited by-同舟云学术

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Published:2017-03 Issue:10072 Volume:389 Page:917-929
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Soria Jean-Charles,Tan Daniel S W,Chiari Rita,Wu Yi-Long,Paz-Ares Luis,Wolf Juergen,Geater Sarayut L,Orlov Sergey,Cortinovis Diego,Yu Chong-Jen,Hochmair Maximillian,Cortot Alexis B,Tsai Chun-Ming,Moro-Sibilot Denis,Campelo Rosario G,McCulloch Tracey,Sen Paramita,Dugan Margaret,Pantano Serafino,Branle Fabrice,Massacesi Cristian,de Castro Gilberto

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK;Shaw;J Clin Oncol,2009

3. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

4. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers;Katayama;Sci Transl Med,2012

5. Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): potential implications for management;Otterson;J Clin Oncol,2012

Cited by 936 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy;Current Protein & Peptide Science;2024-09

2. Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study;JTO Clinical and Research Reports;2024-09

3. Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?;Expert Opinion on Therapeutic Targets;2024-08-19

4. Treatment of ALK-positive non-small cell lung cancer (literature review);Practical oncology;2024-08-02

5. Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer;Journal of the Formosan Medical Association;2024-08